456 related articles for article (PubMed ID: 28265786)
1. Precision medicine driven by cancer systems biology.
Filipp FV
Cancer Metastasis Rev; 2017 Mar; 36(1):91-108. PubMed ID: 28265786
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
3. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
Kensler TW; Spira A; Garber JE; Szabo E; Lee JJ; Dong Z; Dannenberg AJ; Hait WN; Blackburn E; Davidson NE; Foti M; Lippman SM
Cancer Prev Res (Phila); 2016 Jan; 9(1):2-10. PubMed ID: 26744449
[TBL] [Abstract][Full Text] [Related]
4. Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.
Regan-Fendt KE; Xu J; DiVincenzo M; Duggan MC; Shakya R; Na R; Carson WE; Payne PRO; Li F
NPJ Syst Biol Appl; 2019; 5():6. PubMed ID: 30820351
[TBL] [Abstract][Full Text] [Related]
5. Histiocytic neoplasms in the era of personalized genomic medicine.
Durham BH; Diamond EL; Abdel-Wahab O
Curr Opin Hematol; 2016 Jul; 23(4):416-25. PubMed ID: 27101528
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibitors in oncology: a patent review (2015-Present).
Mahapatra DK; Asati V; Bharti SK
Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
[TBL] [Abstract][Full Text] [Related]
7. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
8. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
9. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
10. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
11. Systems Biology of Metabolism: A Driver for Developing Personalized and Precision Medicine.
Nielsen J
Cell Metab; 2017 Mar; 25(3):572-579. PubMed ID: 28273479
[TBL] [Abstract][Full Text] [Related]
12. Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.
Coyle KM; Boudreau JE; Marcato P
Biomed Res Int; 2017; 2017():9620870. PubMed ID: 28685150
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
14. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
15. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
17. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
18. Future of personalized medicine in oncology: a systems biology approach.
Gonzalez-Angulo AM; Hennessy BT; Mills GB
J Clin Oncol; 2010 Jun; 28(16):2777-83. PubMed ID: 20406928
[TBL] [Abstract][Full Text] [Related]
19. Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems.
Parodi S; Riccardi G; Castagnino N; Tortolina L; Maffei M; Zoppoli G; Nencioni A; Ballestrero A; Patrone F
Methods Mol Biol; 2016; 1386():181-219. PubMed ID: 26677185
[TBL] [Abstract][Full Text] [Related]
20. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
